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Abstract
Natural products have an important role in the discovery of analgesic drugs along with 
the determining of the complex mechanisms involved in pain transmission and pain 
relief. Lately, several substances with antinociceptive actions have been purified from 
natural sources and further identified, resulting in novel structural classes and more 
understanding of the underlying pharmacological mechanisms of actions. Yet, natural 
products still hold great potential for the discovery of novel agents for treatment of pain 
disorders and potentially drug addictions with exciting pharmacological profiles (i.e. no 
side effects, no addictive potential). The aim of this chapter is to highlight some active 
compounds derived from natural sources that possess analgesic properties. Additionally, 
the identification of new compounds derived from natural sources could lead to great 
understanding of the underlying pharmacological mechanisms of action, which will be 
addressed in this chapter as well.
Keywords: plant-derived compounds, analgesic properties, pharmacological mechanisms  
of action
1. Introduction
At the present time, many formulas for the relief of pain are present; among them, medicinal 
herbs are highlighted because of their wide popular use and availability. Many plant-derived 
compounds could offer valuable therapeutic effects for the treatment of chronic inflammatory 
conditions, which are likely associated with pain.
In the drug market today, about 40% of all medicines have been originated directly or indi-
rectly from natural sources. It is estimated that about 25% being derived from plants, 13% 
from microorganisms and 3% from animals. For instance, morphine, salicin, artemisinin, 
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 capsaicin, atropine, pilocarpine, digitalis, quinine, scopolamine and captopril are examples of 
drugs derived from natural sources [1, 2].
2. Active compounds derived from natural sources possessing  
analgesic properties
Since ancient times, many active compounds originated from natural sources have been con-
sumed for various medical purposes including the management of pain. Opium, for example, 
has been used since 7000 years ago. Up to the nineteenth century, other active components 
derived from different natural remedies were identified, purified and utilized. Since then, 
analogues have been made from natural sources, and completely synthetic compounds based 
on natural pharmacophores have been introduced into the market [3].
2.1. Aspirin
Aspirin or acetylsalicylic acid (Figure 1) is extracted from the bark of the Willow tree Salix 
alba, family Salicaceae. It is one of the most extensively used analgesic agents for the man-
agement of mild pain. Aspirin is considered the first nonsteroidal anti-inflammatory drug 
(NSAID) that inhibits the arachidonic acid pathway resulting in the synthesis of eicosanoids, 
which is a potent pain mediator [4]. Moreover, the inhibition of the cyclooxygenase (COX) 
enzymes by aspirin led to the discovery of other synthetic NSAIDs.
For instance, the study of the biochemical cascade of COX system led to the discovery of 
the COX-2 enzyme inhibitors. COX-2 inhibitors are believed to be safer than other NSAIDS 
that inhibit the COX-1 enzyme. Rofecoxib (Vioxx)® is an example of a compound that 
selectively targets the COX-2 enzyme, and it was voluntarily withdrawn by Merck and Co., 
Inc. on September 30, 2004, from the US drug market due to an increased risk of cardiovas-
cular effects [5].
2.2. Opioids
Natural opiates and synthetic opioids are potent analgesics that bind to receptors for endog-
enous opiates in the central nervous system (CNS). Opioid is the common name for all com-
Figure 1. Aspirin.
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pounds acting on opioid receptor as the constituents of opium, to produce morphine-like 
effects. Papaver somniferum (family: Papaveraceae) is one of the oldest medicinal plants known 
by mankind, and abuse of its opium juice has been known before history was recorded. 
Opium contains about 25 alkaloids, including morphine (Figure 2), codeine (Figure 3) and 
thebaine (Figure 4) [6]. Tramadol is a synthetic analogue of codeine that acts by binding to 
μ (mu) opiate receptors, added to that it inhibits norepinephrine and serotonin reuptake 
[7]. Whereas, by modifying the chemical structure of thebaine, a semisynthetic derivative 
is obtained, termed oxycodone [8]. The endogenous opioid receptor system includes four 
receptor subtypes designated as mu (μ), delta (δ), kappa (k) and opioid receptor like (ORL-1) 
receptors. These receptors are widely disseminated in the mammalian system and have been 
found in all vertebrates. Opioid receptors are highly distributed in the CNS, including the 
brain and spinal cord, but they are also found in the gastrointestinal system and in the cells 
of immune system [9].
Lately, newly discovered chemical structures have appeared in the literatures that interact 
either with opioid receptors directly or through some other mechanism of controlling opioid 
receptor signalling. These compounds are interesting from a drug design perspective as most 
of them do not contain nitrogen.
Figure 2. Morphine.
Figure 3. Codeine.
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2.2.1. Morphine
In the 1850s, morphine began to be used for chronic pain, in minor surgical operations and 
after surgery. Morphine is the most abundant opiate obtained from opium. It is the dried 
latex obtained by shallow slicing of the unripe seedpods of Papaver somniferum. Meperidine 
was the first synthetic opioid analgesic, with a completely different structure from that of 
morphine, and its analgesic properties were identified in 1939. Far ahead in 1942, nalor-
phine was obtained, as the first opioid receptor antagonist, by replacing the substituent 
group on the nitrogen atom. By replacing the allyl group with the methyl group, nalor-
phine (Figure 5) is obtained from morphine, and naloxone is obtained from oxymorphine 
(Figure 6) [10, 11].
Nalorphine acts as an antagonist at the μ and δ receptors, but it acts as a weak agonist at the 
k receptor, and thus gives slight analgesia. However, nalorphine has hallucinogenic side 
effects. Whereas, naloxone is an antagonist at the three opioid receptors (μ, δ and k recep-
tors). This compound is used to elucidate the possible roles of opioids in response to stress 
[11, 12].
In spite of the remarkable efforts by researchers to discover safe, effective and nonaddictive 
opioids for pain treatment, morphine remains the most valuable painkiller in contemporary 
medicine [13].
Figure 5. Nalorphine.
Figure 4. Thebaine.
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The pharmacological properties of morphine are somewhat complex and varying accord-
ing to the dose, site of action, route of administration and animal species. Morphine is 
mostly considered as pain perception modifier, resulting in an increase in the threshold of 
painful stimuli. Nowadays, analgesia induced by morphine is known to be mediated via 
activation of membrane opioid receptors, and consequently, it can be inhibited by opioid 
receptor antagonists, as naloxone. Furthermore, certain undesirable side effects of mor-
phine as euphorogenic effect, inhibition of gastrointestinal transit time, constipation, loss 
of appetite, hypothermia, bradycardia and retention of urine seem to involve receptor-
mediated actions [14].
As more chemical components of traditionally used plants for the treatment of pain are expli-
cated, there is a great potential for the development of novel drug treatments acting through 
opioid receptors. Indeed, some newly discovered chemical structures have been published in 
the literatures that interact either directly with opioid receptors or through some other mecha-
nisms of controlling opioid receptor signalling. In the next section, examples of some of those 
chemical structures will be reviewed.
2.2.2. Menthol
Menthol (Figure 7) is isolated from peppermint (Menthapiperita, family: Lamiaceae). For many 
centuries, menthol was utilized as an antipruritic, antiseptic and a coolant in topical prepara-
tions as it causes a feeling of coolness due to stimulation of ‘cold’ receptors by inhibiting Ca2+ 
currents of neuronal membranes. It has also been reported that modulation of Ca2+ currents is 
involved in the regulation of pain threshold. Indeed, the inhibition of Ca2+ currents by admin-
istration of voltage-sensitive Ca2+ channel blockers can produce antinociception in labora-
tory animals. Lately, it was evaluated in the hot plate and acetic acid writhing tests where 
it revealed potent activity through interaction with opioid receptors, and more selectively, 
kappa opioid receptors activation [15].
2.2.3. Salvinorin A
Salvinorin A (Figure 8), isolated from Salvia divinorium (Lamiaceae, formerly Labiatae), was 
first described in nonnitrogenous selective kappa opioid receptor ligand. Salvinorin A acts as 
k opioid receptors agonist in spinally mediated pain. There is a great attention for k opioid 
Figure 6. Naloxone.
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receptor agonists among the pharmaceutical industry field [3, 16]. The ethnopharmacologi-
cal uses of Salvia divinorium extract leaves being used to relief headaches, as a sedative, and 
for the treatment of some gastrointestinal disorders since the anatomical location of k opioid 
receptors in brain, spinal cord, GI tract, etc [17].
Unfortunately, k opioid receptor agonists produce unwanted side effects; thus, they are not 
commonly prescribed as analgesics. In this consent, salvinorin A has been reported to cause 
dysphoric hallucination when administered in human [18, 19]. Nonetheless, it is still listed 
as a chemical of concern by the United States Drug Enforcement Agency and is currently 
allowed to be marketed as alternative to other illegal hallucinogens.
2.2.4. Mitragynine
Mitragynine is a nitrogen-containing compound with a unique structure. It is derived from 
the traditional Thai herb Mitragyna speciosa (Rubiaceae). The herb has been used for many years 
in Thailand as a replacement for opium and used by drug addicts seeking for relief dur-
ing opioid withdrawal stage. However, the use of M. speciosa is currently illegal in Thailand, 
Malaysia, South Korea and Australia, but widely available in the United States and UK [20–22].
At least two compounds have been identified in M. speciosa by Takayama ‘’in Ref. [23]”, both 
having opioid receptor activity. The first compound termed mitragynine (Figure 9) is one of the 
Figure 7. Menthol.
Figure 8. Salvinorin A.
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major alkaloidal components. It is a corynanthe based acting as a partial opioid receptor ago-
nist, with about 26% the activity of morphine. The other and the more interesting compound 
is 7-hydroxymitragynine (mitragynine hydroxyindolenine) (Figure 10), with activity of 1000 
times or more than that of morphine.
Mitragynine is ingested orally by chewing fresh leaves or by drinking a tea brewed with the 
substance. The medicinal properties of this plant had been previously described in combating 
fatigue and to tolerate hard work, due to its opium-like effect at high doses and cocain-like stim-
ulant effect at low doses. However, death was reported as a result of mitragynine abuse [24, 25].
2.3. Capsaicin
Capsicum genus, which produces both chilli peppers and bell peppers, belong to the family 
of Solanaceae. Capsicum is originated in Central and South America and has more than 20 
 species that are widely spread around the world. Indeed, only five species are widely culti-
vated including: C. annuum, C. chinense, C. frutescens, C. pendulum and C. pubescens [26].
It seems that capsicum species are among the oldest cultivated plants in the world (5200–3400 
BC). Scientists have found an evidence of people who consumed peppers in Mexico as early 
as 7000 BC; this was the oldest document of capsicum use [27]. Högyes (1878) was the first to 
make evident that the alcoholic extract of paprika (Capsicum annuum) resulted in hypothermia 
when administered systemically [28].
Figure 9. Mitragynine.
Figure 10. Mitragynine hydroxyindolenine.
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Interestingly, the study of pungent principles began in the 1810s using the names “capsicol”, 
“capsicin”, “capsacutin”, etc. Later, capsaicin is the active principle isolated from Capsicum 
species by Thresh in 1846 [29] (Figure 11). The exact chemical structure of capsaicin was 
identified after half a century by Nelson in 1919 [30]. Capsaicin is considered as the most 
prominent  component in plants belonging to Capsicum species, with about 70% of the total 
pungent acid amides and 30% or less constituting dihydrocapsaicin, an analogue of capsaicin 
(capsaicinoid) [14, 31].
Despite the unwanted primary irritant effect of capsaicin to the mucous membranes and the 
eyes, it is used clinically for the management of neuropathic pain syndromes and arthritis [1, 
3]. The Native Americans used Capsicum to treat cramps, diarrhoea and indigestion. Other 
folk medicinal uses of capsaicin include enhancement of appetite, treatment of gastric ulcers, 
rheumatism and restoration of hair growth [32].
The biological effects of capsaicin (8-methyl-N-vanillyl-6-nonenamide) are biphasic: first by 
the excitation of the primary afferents and the second phase involves desensitization or inac-
tivation of neurons [33]. Capsaicin stimulates the afferent sensory neurons that conduct the 
nociceptive information to the central nervous system (CNS), precisely the C and Aδ fibres. 
The stimulatory effect is mainly through calcium influx, the release of several neuropep-
tides including tachykinins, calcitonin gene-related peptide (CGRP) and somatostatin. It also 
blocks the intra-axonal transport of macromolecules, such as the neural growth factor (NGF) 
[27]. Additionally, capsaicin is a vanilloid receptor -1 (VR1) agonist. It is known to have an 
inhibitory effect on nitric oxide (NOx) production in macrophages; this effect clarifies its 
implications in the pathogenesis of inflammatory diseases [3, 34].
2.4. Aconitum alkaloids
Aconitum species, family Ranunculaceae, known by different names such as aconite, monks-
hood, wolf’s bane, women’s bane, Devil’s helmet or blue rocket. Aconitum plants (mainly 
A. japonicum Thunberg and A. carmichaeli Debeaux) have been used from the time of historic 
civilizations in Ayurvedic, Chinese, Tibetan and Greco-Roman medicines for their various 
Figure 11. Capsaicin.
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pharmacological effects. Plants of Aconitum genus were familiar in the European countries’ 
medicine in the nineteenth century  [35].
Leaves and roots of Aconitum plant were used to relieve neuralgic pain, particularly in the 
face to relieve the pain of sciatica. The root is extremely bitter; its paste is applied in acute 
rheumatism also on cuts and wounds as an anti-inflammatory and antiseptic agent [36].
There are two groups of Aconitum alkaloids revealing strong to moderate analgesic prop-
erties. The first group includes aconitine-like diester alkaloids with strong analgesic activ-
ity: aconitine (Figure 12), hypaconitine, mesaconitine, 3-acetylaconitine, bulleyaconitine, 
and yunaconitine. The second group involves less-toxic alkaloids having moderate analgesic 
effect. One of them, lappaconitine (Figure 13), it is believed that lappaconitine and its deacety-
lated analogue have lower toxicity than aconitine and, consequently, it is assumed to be safely 
used as analgesic or anaesthetic agents [35].
Aconitine, 3-acetylaconitine and hypaconitine revealed high affinity Na+ channel ligands, 
thus having antinociceptive, strong arrhythmogenic effects and high acute toxicity, and 
induce a blockade of neuronal conduction by a permanent cell depolarization. In contrast, 
lappaconitine has lower affinity for Na+ channel and thereafter has lesser antinociceptive 
and lesser cardiotoxic activity, acting as a local anaesthetic. Other alkaloids with lower 
Na+ channel affinity such as lappaconidine and oxydelcorine have no antinociceptive effect 
Figure 12. Aconitine.
Figure 13. Lappaconitine.
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[37]. Despite the large number of alkaloids isolated and identified from Aconitum sp. with 
antinociceptive effect, their cardiotoxic actions hindered their clinical use as analgesics [14].
2.5. Polygodial sesquiterpenes
Polygodial sesquiterpene is the major constituent present in the bark of Drymis winteri 
(Winteraceae) and related species, a well-known medicinal plant found in some South American 
countries such as Brazil. Drymis winteri is commonly used in folk medicine as an anti-inflam-
matory and for the treatment of asthma and allergy [38]. Phytochemical investigations of D. 
winteri demonstrated the occurrence of sesquiterpenes, lactones and flavonoids [39, 40].
As well, previous studies [40–42] indicated that a mixture of at least three sesquiterpenes, iden-
tified as being polygodial (Figure 14), 1-β-(ρ-methoxycinnamoyl polygodial and drimanial 
(Figure 15), appear to be the main constituents present in the park of plant D. winteri that are 
accountable for the marked antinociceptive, anti-inflammatory and anti-allergic effects of the 
crude extract. With regard to the relatively high concentrations of polygodial and to a lesser 
extent, drimanial in the park of D. winteri, it can be proposed that the two  sesquiterpenes are the 
most relevant active compounds and are responsible for the major pharmacological activities 
of the plant.
Figure 14. Polygodial.
Figure 15. Drimanial.
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The precise site of action by which polygodial induces antinociception is still under investiga-
tion. The modulatory role of polygodials as antinociceptives as proposed to be via the interaction 
with an opiate-like system through k and δ receptors, the α1-adrenergic receptor, the serotonin-
ergic system, and an interaction with a Gi/o protein pertussis toxin-sensitive mechanism. Thus, 
polygodial or its derivatives might be concerned in the development of new analgesic drugs for 
controlling neurogenic pain [40, 43].
2.6. Caffeine
Caffeine is an alkaloid present in over 60 plant species. Caffeine (1,3,7-trimethylxanthine) is 
mainly in beverages derived from coffee beans, tea leaves and kola nuts (Cola acuminate, fam-
ily: Sterculiaceae). Caffeine has been used medicinally together with ergotamine for migraine 
headaches and in combination with nonsteroidal anti-inflammatory drugs in analgesic prepa-
rations [44]. Moreover, caffeine is believed to be potentially effective cancer chemopreventive 
metabolite in terms of its antioxidant capacity [45].
Caffeine was isolated in 1820, but the precise structure of this methylxanthine was established 
in the last decade of the nineteenth century. Its properties were not fully recognized until 
1981, when the stimulating properties of caffeine and its analogues by the blockade of adenos-
ine receptors were allied [46].
Cola nut is native of West Africa, which has been introduced to the West Indies. It is used in 
large quantities in the soft drink industry. The active principles are caffeine (Figure 16) and 
theobromine (Figure 17), which are both stimulants [44].
Caffeine increases alertness, awareness and attention span, has stimulatory effects on mood 
and sense of wellbeing, and produces an increase in exercise tolerance. Other desirable 
 physiologic effects involve protection of the cerebral vasculature by means of enhancing glu-
cose metabolism. In this concern, it is believed that caffeine consumption has been associated 
with a reduced risk of Parkinson disease. It also constricts cerebral blood vessels, which is a 
highly desirable action in patients with migraine [47]. Caffeine is prescribed as a stimulant of 
the central nervous system and to treat postprandial hypotension and obesity, and also, it is 
indicated for treatment of apnoea in premature neonates [48].
Figure 16. Caffeine.
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Following oral intake, maximum plasma concentration arises between 30 min and 2 h, which 
may be prolonged with food ingestion. Caffeine is readily absorbed by the gastrointestinal 
tract, with 100% bioavailability and high solubility both in aqueous and nonpolar organic 
solvents. Caffeine is lipophilic with low protein binding. Its plasma protein binding—mainly 
albumin—is 10–35%. Caffeine rapidly crosses cell membranes, as well as the placental barrier, 
blood brain, producing drug levels in the brain and cerebrospinal fluid similar to those in 
plasma [46, 49].
In 1985, Burnstock and Kennedy cited that methylxanthines block purinergic receptors type 1 
(P1) and have no effect on P2 receptors [50]. Added to that, the proposed mechanism of action 
of caffeine seems to be related to the blockade of peripheral and central adenosine receptors 
involved in the regulation of pain transmission, giving rise to its analgesic properties [14, 51].
2.7. Ginsenosides
Ginseng, the root of Panax ginseng (Araliaceae), has been reported to relieve a variety of ailments. 
Studies showed that ginseng saponins, which consist of various ginsenoids (Figure 18), are the 
most pharmacoactive constituent of ginseng root. Ginsenoids are believed to be involved in 
pain modulation as well as in opioid-induced antinociception and tolerance [52, 53].
In traditional folk medicine, ginseng has been used to relieve some types of pain such as tooth-
ache, abdominal pain, chest pain and neuralgia. A line of evidence also shows that ginseng 
Figure 17. Theobromine.
Figure 18. Ginsenosides.
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saponins are responsible for relieving pain induced by chemicals or noxious heat in experi-
mental animals [54].
Most ginseng species possess active naturally occurring constituents such as the ginsenosides, 
polysaccharides, peptides, polyacetylenic alcohols and fatty acids. From the ginseng saponin 
fraction, more than 30 triterpene ginsenoside derivatives containing sugars were isolated. Yet, 
there is a wide variation (2–20%) in the ginsenoside content among the different ginseng spe-
cies [2].
Ginseng saponins inhibit voltage-dependent Ca2+ channels providing one possible expla-
nation for its analgesic efficacy because sensory neurons transfer sensory information 
such as pain from the peripheral nervous system toward the central nervous system [55]. 
Furthermore, the regulation of voltage-dependent Ca2+ channels by ginseng saponins is not 
mediated through the inhibitory receptors such as opioids, ɑ2-adrenergic, GABAergic, nor 
muscarinic receptors [53].
3. Pharmacological mechanisms of action for naturally derived  
analgesic drugs
Interestingly, the identification of new compounds derived from natural sources with 
potential antinociceptive effect could lead to great understanding of the underlying phar-
macological mechanisms of action. Herein, the next section, we will review some targeted 
pharmacological mechanisms of action for naturally derived analgesic drugs.
3.1. Voltage-gated ion channels
Many natural products have been found to interact with voltage-gated ion channels. Some 
more recent natural products are to be studied at the Na+, K+ and Ca2+channels. These com-
pounds cause their effects through several mechanisms of action.
Voltage-gated Na+ channels play a central role in the generation and dissemination of action 
potentials in neurons and other cells such as skeletal muscle and cardiac cells. Modulators of 
sodium channels are being used as local anaesthetics, antiarrhythmics, analgesics and antiepi-
leptics, and for other disorders [56]. In this aspect, tetrodotoxin, isolated from the puffer fish, 
blocks sodium channels and causes great harm to those that ingest it leading to numbness 
in the lip and tongue within 20 min of ingestion followed by paralysis and may cause death. 
Consequently, the use of tetrodotoxin as a key compound for analgesic development has been 
limited by its toxic nature [3].
As well, voltage-gated K+ channels have been shown to be involved in pain processes. 
Activation of potassium channels leads to membrane hyperpolarization then inhibition of 
cell excitability. Those pain signals may be transmitted either directly or indirectly depend-
ing on the location of these channels. Today, several anaesthetics are used clinically to 
work through interactions with potassium channels [57]. Certain peptides from natural 
sources have been identified to act through potassium channels. For instance, tertiapin, a 
peptide with 21 amino acids, isolated from the venom of the honey bee, has been shown 
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to block inward rectifier potassium channels [58]. Moreover, administration of tertiapin in 
mice diminished the analgesic response evoked by spinal administration of high doses of 
morphine [59]. Further research in this area may result in better understanding of the pain 
modulation responses, managing drug addiction, and may lead to the discovery of new 
analgesic compounds.
Furthermore, voltage-gated Ca2+ channel activation directly affects membrane potential and 
contributes to the electrical excitability of neurons. Voltage-gated Ca2+ channels have an 
important role in the release of neurotransmitter from the presynaptic terminals in the dorsal 
horn in response to inward action potentials [60]. In this aspect, a peptide termed N-agatoxin 
isolated from the venom of the funnel web spider, and an American spider Agelenopsis aperta 
inhibits P/Q-type calcium channels that have been reported to play a role in migraine and 
headaches [61, 62]. Future research on the functional role of P/Q-type calcium channels may 
provide an additional target for the modulation of pain responses.
3.2. Acetylcholine receptors
Two classes of acetylcholine receptors are well-known, the muscarinic and the nicotinic 
acetylcholine receptors. Both classes were recognized through the utilization of the natural 
products, muscarine and nicotine, respectively. The role of these receptors in modulating the 
central nociception has been well-documented. The muscarinic acetylcholine receptors have 
several known natural product ligands including: hyoscyamine, atropine, scopolamine and 
Mamba snake toxins [3].
Epibatidin, an alkaloid isolated from the skin of the Ecuadorian dart-frog, Epipedobates tricolor, 
has been reported to be a potent nicotinic analgesic. It could be antagonized by mecamyla-
mine, a nicotinic receptor antagonist [63]. Accordingly, it was established that epibatidine 
as a powerful tool for studying nicotinic pathways involved in pain perception. As well, its 
remarkable efficiency as an antinociceptive may be due to the selective effects on central anti-
nociceptive pathways [64].
3.3. Cannabinoid receptors
Two cannabinoid receptors, CB1 and CB2, have been identified and subsequently cloned. 
They belong to G-protein coupled receptors family, sharing 44% amino acid sequence homol-
ogy but vary in their anatomical distribution. Expression of CB1 receptor is mainly in the CNS 
and to a lesser extent in other tissues, while CB2 receptor is primarily expressed in peripheral 
tissues associated with immune functions, including macrophages, B and T cells, as well as in 
peripheral nerve terminals and on mast cells [65].
The endogenous family of ligands that interact with these receptors is known as the anan-
damides (N-arachidonoyl-ethanolamine). They are lipid in nature with antinociceptive activ-
ity but not as potent as tetrahydrocannabinol (THC) [66]. Interestingly, neurons in the brain 
produce, release and inactivate anandamide, confirming a role for this arachidonate deriva-
tive as an endogenous cannabinoid substance [67].
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Remarkably, a nonnitrogenous lipophilic molecule, Δ9-tetrahydrocannabinol (Δ9-THC), 
isolated from Cannabis sativa, is the prototypical ligand, interacting with the cannabinoid 
G-protein coupled receptors [68]. It has also been reported that another constituent cannabi-
dol isolated from C. sativa exerts important anti-inflammatory activity. Cannabinoid recep-
tor agonists induce a number of unwanted CNS effects, which are supposed to be mediated 
mainly by the central distribution pattern of CB1 receptors [65].
3.4. Vanilloid receptors
Vanilloid receptors (VR), or vanilloid-gated ion channels, also known as capsaicin recep-
tors, have been shown to be involved in nociception [69]. Nonetheless, their clinical potential 
remains to be proven. Vanilloid receptors are expressed almost exclusively by primary sen-
sory neurons involved in nociception and neurogenic inflammation.
It is well established that the VR agonists give rise to excitatory effects characterized by noci-
ception and neurogenic inflammation, followed by desensitization [14, 70]. Notably, many 
natural products are known as modulators of these receptors. Capsaicin, for example, is a 
VR1 receptor agonist and is marketed in the United States in topical preparations for the 
treatment of arthritis and inflammatory joint pain. At the present time, it is believed that VR1 
receptor agonists can be good attractive therapeutic target. Interestingly, other “hot” spices, 
like piperine and zingerone, the active ingredients in black pepper and ginger, respectively, 
also appear to act through VR activation [71].
Peripheral fibres are the site of release of a variety of neuropeptides among which substance 
P (SP) and calcitonin gene-related peptide (CGRP) are defined. Depletion of SP and CGRP as 
well as of vanilloid receptors occurred following treatment with capsaicin, in the spinal and 
peripheral terminals of capsaicin sensitive neurons in almost 24 h [28].
Other naturally occurring compound acting at VR1 receptors is of fungal origin, a triprenyl 
phenol, termed scutigeral, a novel structural class of VR ligand. Scutigeral, isolated from the 
non-pungent edible mushroom Albatrellus ovinus, has been shown to stimulate rat dorsal root 
ganglion neurons by activation of vanilloid receptors [72].
3.5. Purinergic P2X receptors inhibitors
One pharmacological target in the area of analgesics and anti-inflammatory agents is puriner-
gic P2X receptors (P2XR), which are important receptors in the modulation of  inflammation 
and pain. In 1978, Burnstock [73] mentioned the existence of two classes of purinergic 
receptors, known as receptors P1 (adenosine) and P2 (adenosine 5’-triphosphate, ATP) [50]. 
Markedly, mammalian ATP-gated nonselective cation channels (P2XRs) consist of seven 
potential subunits; denoted P2X1 to P2X7 [74].
In 1995, a significant advance was made when the P2X3 ionotropic ion channel purinergic 
receptor was cloned and presented to be mainly localized on small nociceptive sensory neu-
rons in dorsal root ganglia (DRG) [75]. Shortly, Burnstock [76] suggested a unifying purinergic 
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hypothesis for the initiation of pain that ATP released as a co-transmitter with noradrena-
line (NA) and neuropeptide Y from sympathetic nerve terminal varicosities probably that is 
involved in activating these receptors in three different pain conditions: as a co-transmitter 
from sympathetic nerves in sympathetic pain as causalgia and reflex sympathetic dystrophy; 
from endothelial cells in vascular pain, including migraine and angina; and from tumour cells 
in cancer.
Likewise, purinergic mechano-sensory transduction has been implicated for visceral pain. 
Meanwhile, ATP released from urothelial cells and epithelial cells lining intestine during the 
distension acts on P2X3 and P2X2/3, and perhaps P2Y, receptors on subepithelial sensory 
nerve fibres to initiate impulses in sensory pathways to the pain centres in the brain as well 
as triggering local reflexes. Besides, P1, P2X and P2Y receptors are possibly implicated in 
nociceptive neural pathways in the spinal cord, while P2X4 receptors on the spinal microglia 
are involved in allodynia [77].
Of the seven subtypes of P2XR, the types that are most related to the progression or control of 
pain status are the P2X3R, the heteromericeP2X2/3R, P2X4R, and the P2X7R [78].
An example of natural inhibitor of purinergic receptors is a product known as puerarin. 
Puerarin is an isoflavone isolated from a traditional Chinese herb (Radix puerariae). It was 
found to have an inhibitory effect on burn pain hyperalgesia through inhibiting the upregula-
tion of the P2X3R protein expression in the dorsal root ganglion neurons [79].
Also, purotoxin, a peptide isolated from the venom of the Asian spider Geolycosasp, also 
showed a potent and selective antagonist effect on P2X3R, inhibiting the ionic current in rat 
neurons and showing an analgesic effect on inflammatory pain [78].
4. Conclusion
Natural products are an extremely valuable source of novel compounds with potential anal-
gesic properties. More research needs to be conducted on natural products to discover new 
compounds, and hereafter, new mechanisms of actions will be elucidated.
Lastly, the fields of pharmacognosy, medicinal chemistry and pharmacology are expected 
to work closely to ensure that novel naturally driven compounds are explored for their 
potential development as novel drugs as well as their pharmacological mechanisms of 
action.
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Footnotes
Chemical structures that cite in the current chapter are taken from those provided on submit-
ted PubChem chemical compound records, as follows:
 ⁻ Aconitine: National Center for Biotechnology Information. PubChem Compound 
Database; CID=2012, https://pubchem.ncbi.nlm.nih.gov/compound/2012. 
 ⁻ Aspirin: National Center for Biotechnology Information. PubChem Compound Database; 
CID=2244, https://pubchem.ncbi.nlm.nih.gov/compound/2244. 
 ⁻ Caffeine: National Center for Biotechnology Information. PubChem Compound Database; 
CID=2519, https://pubchem.ncbi.nlm.nih.gov/compound/2519. 
 ⁻ Capsaicin: National Center for Biotechnology Information. PubChem Compound 
Database; CID=1548943, https://pubchem.ncbi.nlm.nih.gov/compound/1548943.
 ⁻ Codeine: National Center for Biotechnology Information. PubChem Compound Database; 
CID=5284371, https://pubchem.ncbi.nlm.nih.gov/compound/5284371.
 ⁻ Drimanial: National Center for Biotechnology Information. PubChem Compound 
Database; CID=636975, https://pubchem.ncbi.nlm.nih.gov/compound/636975. 
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 ⁻ Ginsenosides: National Center for Biotechnology Information. PubChem Compound 
Database; CID=9852086, https://pubchem.ncbi.nlm.nih.gov/compound/9852086. 
 ⁻ Lappaconitine: National Center for Biotechnology Information. PubChem Compound 
Database; CID=115161, https://pubchem.ncbi.nlm.nih.gov/compound/115161.
 ⁻ Menthol: National Center for Biotechnology Information. PubChem Compound Database; 
CID=16666, https://pubchem.ncbi.nlm.nih.gov/compound/16666.
 ⁻ Mitragynine hydroxyindolenine: National Center for Biotechnology Information. 
PubChem Compound Database; CID=44301524, https://pubchem.ncbi.nlm.nih.gov/
compound/44301524.
 ⁻ Mitragynine: National Center for Biotechnology Information. PubChem Compound 
Database; CID=3034396, https://pubchem.ncbi.nlm.nih.gov/compound/3034396.
 ⁻ Morphine: National Center for Biotechnology Information. PubChem Compound 
Database; CID=5288826, https://pubchem.ncbi.nlm.nih.gov/compound/5288826.
 ⁻ Nalorphine: National Center for Biotechnology Information. PubChem Compound 
Database; CID=5284595, https://pubchem.ncbi.nlm.nih.gov/compound/5284595.
 ⁻ Naloxone: National Center for Biotechnology Information. PubChem Compound 
Database; CID=5284596, https://pubchem.ncbi.nlm.nih.gov/compound/5284596.
 ⁻ Polygodial: National Center for Biotechnology Information. PubChem Compound 
Database; CID=72503, https://pubchem.ncbi.nlm.nih.gov/compound/72503. 
 ⁻ Salvinorin A: National Center for Biotechnology Information. PubChem Compound 
Database; CID=128563, https://pubchem.ncbi.nlm.nih.gov/compound/128563.
 ⁻ Thebaine: National Center for Biotechnology Information. PubChem Compound Database; 
CID=5324289, https://pubchem.ncbi.nlm.nih.gov/compound/5324289.
 ⁻ Theobromine: National Center for Biotechnology Information. PubChem Compound 
Database; CID=5429, https://pubchem.ncbi.nlm.nih.gov/compound/5429. 
(All accessed Dec 4, 2016)
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